Business
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity -
About this update from Biorestorative Therapies, Inc.
[{"type":"text","content":"- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity - MELVILLE, N.Y., April 30, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it will release its first quarter 2024 financial results after market close on Tuesday, May 14, 2024. \"I look forward to providing more detail on our exciting recently announced transformative commercial partnership with Cartessa, as well as discussing the meaningful progress we are making with our clinical and preclinical development programs, during this, our first-ever quarterly conference call,” said Lance Alstodt, BioRestorative’s CEO. Following the announcement, BioRestorative management will host its inaugural quarterly conference call to review the financial results and provide a business update. First Quarter 2024 Results Conference Call Details: Date:Tuesday, May 14, 2024Time:4:30 p.m. ETDomestic:1-888-506-0062International:1-973-528-0011Access Code:357232 Participants are asked to dial in approximately 10 minutes before the conference call is scheduled to begin. The call can also be accessed via webcast on the Company's website at https://www.biorestorative.com/investor-relations under “Events.” The webcast will be archived and accessible for approximately 90 days. About BioRestorative Therapies, Inc. BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an o...